Picture of Homology Medicines logo

FIXX Homology Medicines Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+3.62%
3m+48.19%
6m-34.3%
1yr-23.51%
Volume Change (%)
10d/3m-41.25%
Price vs... (%)
52w High-37.32%
50d MA+19.9%
200d MA+1.8%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-126.95%
Return on Equity-90.02%
Operating Margin-8015.74%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Homology Medicines EPS forecast chart

Profile Summary

Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company is focused on transforming the lives of patients suffering from rare genetic diseases with unmet medical needs by addressing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or gene therapy to express antibodies platform (GTx-mAb), which is designed to produce antibodies throughout the body. The Company has gene editing and gene therapy clinical-stage programs in phenylketonuria (PKU) and Hunter syndrome (MPS II), a preclinical pipeline that includes a gene therapy candidate for metachromatic leukodystrophy and a GTx-mAb (vectorized antibody) candidate for paroxysmal nocturnal hemoglobinuria, as well as intellectual property on its family of 15 AAVHSCs.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
March 12th, 2015
Public Since
March 28th, 2018
No. of Shareholders
14
No. of Employees
7
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
58,133,540

FIXX Share Price Performance

Upcoming Events for FIXX

Homology Medicines Inc Reverse Split For FIXX.OQ - Ratio 1-18

Q1 2024 Homology Medicines Inc Earnings Release

Homology Medicines Inc Annual Shareholders Meeting

Q2 2024 Homology Medicines Inc Earnings Release

Similar to FIXX

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ